Recent Advances in the Development of Small-molecule CCR5 Inhibitors for HIV

被引：11
|
作者：
Liu, Tao [1 ]
Weng, Zhiyong [1 ]
Dong, Xiaowu [1 ]
Hu, Yongzhou [1 ]
机构：
[1] Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Hangzhou 310058, Zhejiang, Peoples R China
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2010年 / 10卷 / 13期
关键词：
HIV; Entry; Co-receptor; CCR5; Small-molecule inhibitor; Maraviroc; IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR ANTAGONISTS; INFECTION IN-VITRO; BIOLOGICAL EVALUATION; ANTI-HIV-1; AGENTS; HIGHLY POTENT; ANTIVIRAL ACTIVITY; ENTRY INHIBITORS; VIRAL ENTRY; PART;
D O I：
10.2174/13895575110091277
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
CCR5 (C-C chemokine receptor type 5) is a chemokine receptor that has been identified as a major HIV coreceptor in viral entry and therefore is a highly validated target for the development of new anti-HIV drugs. Here, we discuss the insights gained so far relevant to the development of small-molecule CCR5 inhibitors for the treatment of HIV, and highlight small-molecule CCR5 inhibitors that are currently under preclinical and clinical trials.
引用
收藏
页码：1277 / 1292
页数：16
相关论文
共 50 条
  • [21] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S13 - S13
  • [22] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 : S13 - S13
  • [23] A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
    Moore, John P.
    Kuritzkes, Daniel R.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 118 - 124
  • [24] Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5
    Berg, Christian
    Spiess, Katja
    Luttichau, Hans R.
    Rosenkilde, Mette M.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (06):
  • [25] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
    Baba, M
    Nishimura, O
    Kanzaki, N
    Okamoto, M
    Sawada, H
    Iizawa, Y
    Shiraishi, M
    Aramaki, Y
    Okonogi, K
    Ogawa, Y
    Meguro, K
    Fujino, M
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703
  • [26] CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors
    Hu, Q.
    Keele, B.
    Ping, L.
    Grayson, T.
    Sun, C.
    Hahn, B.
    Shattock, R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 6 - 6
  • [27] Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins
    Chen, Siliang
    Pan, Zhaoping
    Liu, Mingxia
    Guo, Linghong
    Jiang, Xian
    He, Gu
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5144 - 5167
  • [28] Recent Advances in the Development of Small-Molecule Compounds Targeting HIV-1 gp41 as Membrane Fusion Inhibitors
    Kawashita, Norihito
    Tian, Yu-Shi
    de Silva, U. Chandimal
    Okamoto, Kousuke
    Takagi, Tatsuya
    MINI-REVIEWS IN ORGANIC CHEMISTRY, 2012, 9 (01) : 20 - 26
  • [29] Small Molecule CCR5 and CXCR4-Based Viral Entry Inhibitors for Anti-HIV Therapy Currently in Development
    Kazmierski, Wieslaw M.
    Gudmundsson, Kristjan S.
    Piscitelli, Stephen C.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 301 - 320
  • [30] A Novel Small-molecule CCR5 Agonist, ESN-196, with Potent R5 HIV-1 Activity
    Ferain, Thierry
    Schols, Dominique
    Bernard, Jerome
    Fraser, Graeme
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A23 - A24
12345